EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases

Daekee Kwon, Kyung-Sun Kang

Frontiers in Bioscience-Landmark · 2026-03-11 · 31 (3)

DOI: 10.31083/fbl48704 ↗

At a glance

Übersichtsarbeit in Frontiers in Bioscience-Landmark, published online on 2026-03-11. Written by Daekee Kwon and 1 co-authors. Institution: Research Institute, Maru Therapeutics Co., Ltd., Seoul BioHub Global Center, Dongdaemun-gu, 02455 Seoul, Republic of Korea. Major MEDLINE topics: T-Lymphocytes, Killer Cells, Natural, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. 18 references. The full text is freely available (open access, CC BY 4.0). Funded by: Korean Fund for Regenerative Medicine (KFRM) grant.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Anticancer therapeutics have evolved from small-molecule drugs to monoclonal antibodies and, more recently, to cell and gene therapies (CGTs). This progress has been driven by the pursuit of greater drug specificity, potency, and safety. Recent breakthroughs in chimeric antigen receptor T-cell (CAR-T) therapy for B-cell hematologic malignancies have accelerated the development of CAR-X CGTs, including CAR-T, CAR-natural killer (CAR-NK), and CAR-macrophage approaches. In this article, we compare candidate CAR-X platforms for T-cell–related diseases, such as T-cell hematologic malignancies, and propose the most suitable modality. Therefore, we analyzed the advantages and limitations of CAR-T, CAR-NK, and CAR-macrophage therapies. In T-cell-related diseases, CAR-T therapy faces multiple challenges, including fratricide, T-cell aplasia, and substantial barriers to the generation of allogeneic CAR-T products. CAR-macrophage therapies, in contrast, are constrained by relatively limited efficacy. In contrast, CAR-NK cells do not cause fratricide or T-cell aplasia and can be manufactured efficiently as allogeneic, “off-the-shelf” products. Collectively, to sustain and extend the advances in CGT initiated by CAR-T cells in B-cell malignancies, prioritizing CAR-NK research infrastructure for T-cell–related diseases represents a rational and strategic approach.

Subjects

MeSH terms (MEDLINE)

T-LymphocytesKiller Cells, NaturalReceptors, Chimeric AntigenImmunotherapy, AdoptiveHematologic NeoplasmsHumansAnimals

Author keywords

adoptive immunotherapyallogeneic cellaplasiacell therapychimeric antigen receptor therapyhematologic neoplasms

Substances

Receptors, Chimeric Antigen

Authors and institutions

  • Research Institute, Maru Therapeutics Co., Ltd., Seoul BioHub Global Center, Dongdaemun-gu, 02455 Seoul, Republic of Korea.
  • Department of Veterinary Medicine, College of Veterinary Medicine, Seoul National University, 08826 Seoul, Republic of Korea.
  • Adult Stem Cell Research Center, College of Veterinary Medicine, Seoul National University, 08826 Seoul, Republic of Korea.

Funding

  • Korean Fund for Regenerative Medicine (KFRM) grant

Cite

APA

Kwon, D., & Kang, K. S. (2026). Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases. Frontiers in Bioscience-Landmark, 31(3). https://doi.org/10.31083/fbl48704

Vancouver

Kwon D, Kang KS. Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases. Frontiers in Bioscience-Landmark. 2026;31(3). doi:10.31083/fbl48704

BibTeX
@article{Kwon2026,
  author = {Kwon, Daekee and Kang, Kyung-Sun},
  title = {Potential Application of CAR-NK Cells as an Ex Vivo Therapy for T-cell-related Diseases},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  volume = {31},
  number = {3},
  doi = {10.31083/fbl48704}
}
Start for free →